Evidence map›Paper›PMID 40330446›Full record

ArticleContemporary oncology (Poznan, Poland)2025

Proteomic analysis reveals potential biomarker candidates in serous ovarian tumors - a preliminary study.

Shona Pedersen, Alaaeldin Ali Mohamed, Hubert Krzyslak, Latifa Saad S A Al-Kaabi, Mohannad Natheef Abuhaweeleh, Ala-Eddin Al Moustafa, Lina Ghabreau, Semir Vranic, Bent Honoré

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shona PedersenCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Alaaeldin Ali MohamedCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Hubert KrzyslakDepartment of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.
Latifa Saad S A Al-KaabiCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Mohannad Natheef AbuhaweelehCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Ala-Eddin Al MoustafaCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Lina GhabreauFaculty of Medicine, University of Aleppo, Aleppo, Syria.
Semir VranicCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Bent HonoréDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ovarian serous cystadenocarcinoma (SCA), a deadly gynecologic cancer, often goes undetected until the late stages. Tissue proteomics unveils disease heterogeneity, enhancing tumor classification and enabling personalized treatments tailored to individual expression profiles. Material and methods: Tissue samples from 46 serous ovarian tumors were quantified using label-free liquid chromatography-tandem mass spectrometry. We identified 80 proteins differentiating SCA from borderline tumors, 277 distinguishing SCA from benign tumors, and 195 between borderline and benign tumors. Ingenuity pathway analysis revealed increased cell proliferation and RNA processing in SCA and borderline tumors compared to benign tumors, with SCA showing greater oxidative phosphorylation than borderline tumors. Results: Our comparative analysis indicates that upregulated (ASS1 - argininosuccinate synthase 1, CAPS, PPA1, BCAT1, MCM4) and downregulated proteins (MUC5B, SLC4A1, tenascin-XB - TNXB, carbonic anhydrase 1, hemoglobin β) may offer a robust panel for distinguishing SCA from benign and borderline ovarian tumors, potentially aiding in early diagnosis and disease monitoring. The cancer-associated proteins pyridoxal dependent decarboxylase domain containing 1 (AUC: 0.83, 95% CI: 0.66-1), GFPT1 (AUC: 0.84, CI: 0.70-0.89), and HYOU1 (AUC: 0.84, CI: 0.70-0.98) significantly differentiated between low-grade (LGSCA) and high-grade serous cystadenocarcinoma (HGSCA). Low-grade SCA showed significantly greater levels of MZB1 (log Conclusions: Argininosuccinate synthase 1 and TNXB showed potential as markers of disease progression. Elevated ASS1 was observed in borderline, LGSCA, and HGSCA tumors compared to benign tumors, while TNXB levels progressively declined from benign to borderline, LGSCA, and HGSCA tumors. Our study pinpoints critical biomarkers in serous ovarian tumors for HGSCA progression.

Indexed as

formalin-fixed paraffin-embedded tissuemass spectrometryovarian cancerprotein biomarkersproteomics

Identifiers

PMID40330446
PMCPMC12051873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.